Patents Assigned to Dept. of Veterans Affairs
-
Publication number: 20140122129Abstract: A system of automated patient history intake including a retrieval system for retrieving pharmaceutical information specific to a patient, a display system for displaying the pharmaceutical information, and a reconciliation system for reconciling the pharmaceutical information using visual data. A system for automated patient check-in including a retrieval system for retrieving pharmaceutical information specific to a patient, a display system for displaying the pharmaceutical information, and a reconciliation system for reconciling the pharmaceutical information using visual data.Type: ApplicationFiled: January 3, 2014Publication date: May 1, 2014Applicant: Dept. of Veterans AffairsInventors: Blake J. LESSELROTH, Robert S. FELDER, Shawn M. ADAMS, Phillip D. CAUTHERS, Gordon J. WONG
-
Patent number: 8691942Abstract: There is provided a novel series of synthetic analogs of hGH-RH(1-29)NH2 (SEQ ID NO: 1) and hGH-RH(1-30)NH2. Of particular interest are those carrying PhAc, N-Me-Aib, Dca, Ac-Ada, Fer, Ac-Amc, Me-NH-Sub, PhAc-Ada, Ac-Ada-D-Phe, Ac-Ada-Phe, Dca-Ada, Dca-Amc, Nac-Ada, Ada-Ada, or CH3—(CH2)10—CO-Ada, at the N-Terminus and ?-Ala, Amc, Apa, Ada, AE2A, AE4P, ?-Lys(?-NH2), Agm, Lys(Oct) or Ahx, at the C-terminus. These analogs inhibit the release of growth hormone from the pituitary in mammals as well as inhibit the proliferation of human cancers, and inhibit the hyperplastic and benign proliferative disorders of various organs, through a direct effect on the cancerous and non-malignant cells. The stronger inhibitory potencies of the new analogs, as compared to previously described ones, result from replacement of various amino acids.Type: GrantFiled: September 25, 2010Date of Patent: April 8, 2014Assignees: University of Miami, U.S.A. Represented by the Dept. of Veterans AffairsInventors: Andrew V. Schally, Marta Zarandi, Jozsef L. Varga, Ren Zhi Cai
-
Patent number: 8435979Abstract: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are triphenyl methane analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, inflammatory, degenerative and vascular diseases, and parasitic infections. The compounds are triphenyl methane analogs of imipramine blue and analogs thereof, as defined herein. The compounds are believed to function by inhibiting tNOX expression, the effects of ROS, and/or the production of HIF2. Thus, the compounds are novel therapeutic agents for a variety of cancers and other diseases.Type: GrantFiled: December 21, 2009Date of Patent: May 7, 2013Assignees: Emory University, The United States of America as represented by the Dept of Veterans AffairsInventor: Jack L. Arbiser
-
Patent number: 8435507Abstract: The present invention relates to immunogenic peptides derived from human prostate cancer antigen (PSA-derived peptides) and their use as vaccines to treat or prevent prostate cancer. The invention is also related to dendritic cells from a patient having prostate cancer, which dendritic cells have been exposed to one or more PSA-derived peptides, and their use to treat or prevent prostate cancer in the patient. The invention is also directed to T-cells from a patient which cells are specific for PSA-activated peptide(s), and their uses to treat or prevent prostate cancer.Type: GrantFiled: August 19, 2005Date of Patent: May 7, 2013Assignees: University of Maryland, The United States of America as Represented by the Dept of Veterans Affairs, Oregon Health & Science UniversityInventors: Richard B. Alexander, Elena N. Klyushnenkova, Jason Link, Arthur Vandenbark
-
Publication number: 20130058932Abstract: The present invention pertains to use of PKC-iota inhibitors for treatment of glioma. In a specific embodiment, the treatment method comprises administering ICA-1 or a salt thereof to a subject with glioma. In another embodiment, the treatment method comprises contacting glioma cells with an effective amount of ICA-1 or a salt thereof.Type: ApplicationFiled: September 4, 2012Publication date: March 7, 2013Applicants: The U.S Govt. as represented by the Dept. of Veterans Affairs, University of South FloridaInventor: Mildred E. Acevedo-Duncan
-
Patent number: 8264458Abstract: The present invention provides variable compliance joysticks with mechanical and software customization, and with an integrated control capability, and a method of systematically determining the best mechanical settings and compensatory algorithms to embed in the joysticks to offer an individual with substantial upper extremity motor impairments a personal fit and maximum function. The joysticks may include components for varying the compliance and dampening of the joystick shaft. The method may include providing the user access to operate the joysticks, operatively connecting the joysticks to a driving simulator, displaying an icon on the driving simulator, controlling movement of the icon by the joysticks, evaluating performance of the user based upon the user's ability to control movement of the icon, and modifying hardware settings and software algorithms for the joysticks based upon the evaluation.Type: GrantFiled: January 13, 2009Date of Patent: September 11, 2012Assignees: Dept. of Veterans Affairs, The University of Pittsburgh of the Commonwealth System of Higher EducationInventors: Rory A. Cooper, Donald Spaeth, Songfeng Guo
-
Publication number: 20120226138Abstract: Disclosed herein are methods for identifying and targeting brain regions and brain structures. In one embodiment, a method of identifying a brain structure in a patient comprises imaging a brain region using Diffusion Tensor Imaging MRI to identify a nerve tract, following the nerve tract to a first brain structure, and identifying the first brain structure based on the location and orientation of the nerve tract.Type: ApplicationFiled: July 21, 2010Publication date: September 6, 2012Applicants: United States Government Dept of Veterans Affairs, The regents of the University of CaliforniaInventors: Antonio Alfonso Ferreira DeSalles, Alejandro Covalin
-
Publication number: 20120213886Abstract: The invention provides for a diet that significantly reduces the glycohemoglobin levels in individuals with type 2 diabetes. A diet plan can be provided to an individual in the form of cards and/or pages with an appropriate meal plan, food items and/or pre-packaged meals, or in an electronic medium for the individuals to use to develop appropriate meal plans. The diet comprises food items having a nutritional composition that consists essentially of 30% protein, 50% fats, and 20% carbohydrates, or food items having a nutritional composition that consists essentially of 30% protein, 40% fats, and 30% carbohydrates, and is consumed for a period of three weeks to one year.Type: ApplicationFiled: February 21, 2012Publication date: August 23, 2012Applicants: U.S. Dept. of Veterans Affairs, Regents of the Univ. of MinnesotaInventors: Mary C. Gannon, Frank Q. Nuttall
-
Patent number: 7875277Abstract: The present invention relates to compositions and methods for detecting and inhibiting squamous cell carcinoma using agents that target the laminin 5 alpha 3 G4-G5 domain.Type: GrantFiled: April 14, 2008Date of Patent: January 25, 2011Assignees: The Dept. of Veterans Affairs Office of The General Counsel, The Board of Trustees of the Leland Stanford Junior UniversityInventor: M. Peter Marinkovich
-
Publication number: 20090105181Abstract: The present invention relates to the use of oxidized nicotinamide adenine dinucleotide (NAD+) or of its reduced form, NADH, as sodium channel modulators. The present invention also relates to the use of compositions containing NAD+ or NADH to treat conditions associated with sodium channel current, such as arrhythmia. NAD+ is found to increase sodium channel current, while NADH is found to decrease sodium channel current. Thus, conditions that are associated with decreased sodium channel current can be treated with NAD+, while conditions that is associated with increased sodium channel current can be treated with NADH.Type: ApplicationFiled: October 17, 2008Publication date: April 23, 2009Applicant: The U.S.A Dept. of Veterans Affairs Technology Transfer Program Office of Research & DevelopmentInventor: Samuel C. Dudley, JR.
-
Patent number: 7452865Abstract: There is provided a novel series of synthetic antagonistic analogs of hGH-RH(1-29)NH2. These analogs inhibit the activity of endogenous hGH-RH on the pituitary GH-RH receptors, and therefore prevent the release of growth hormone. The analogs also inhibit the proliferation of human cancers through a direct effect on the cancer cells. The higher inhibitory potencies of the new analogs, as compared to previously described ones, results from replacement of various amino acids.Type: GrantFiled: July 26, 2004Date of Patent: November 18, 2008Assignees: The Administrare's of the Tulane Educational Fund, United States of America by Dept of Veterans AffairsInventors: Andrew V. Schally, Jozsef Varga, Marta Zarandi, Ren Zhi Cai
-
Publication number: 20080199863Abstract: Described are probes and methods for detecting pathogens and antibiotic resistance of a specimen. The method comprises contacting the specimen with a growth medium; and lysing the specimen to release nucleic acid molecules from the specimen. The lysate of the specimen is contacted with a capture probe immobilized on a substrate, wherein the capture probe comprises an oligonucleotide that specifically hybridizes with a first target nucleic acid sequence region of ribosomal RNA. The lysate is in contact with a detector probe that comprises a detectably labeled oligonucleotide that specifically hybridizes with a second target nucleic acid sequence region of ribosomal RNA. The presence or absence of labeled oligonucleotide complexed with the substrate is determined. Detection of labeled oligonucleotide complexed with the substrate is indicative of the presence of pathogen. Performing the method in the presence and absence of an antibiotic permits detection of antibiotic resistance.Type: ApplicationFiled: May 1, 2007Publication date: August 21, 2008Applicants: The Regents of the University of California, U.S. Government represented by the Dept. of Veterans AffairsInventors: David A. Haake, Bernard M. Churchill, Joseph C. Liao, Marc A. Suchard, Yang Li, Mitra Mastali
-
Publication number: 20070249734Abstract: A method, composition and kit for detecting the presence of a phospholipid, such as phosphatidylserine, on a cell membrane is provided. A binding agent including lactadherin, a fragment of lactadherin, a functional equivalent of lactadherin, or a functional equivalent of a fragment of lactadherin, is used to detect the presence of any phospholipid.Type: ApplicationFiled: June 30, 2004Publication date: October 25, 2007Applicants: THE BRIGHAM & WOMEN'S HOSPITAL, INC., U.S. DEPT. OF VETERANS AFFAIRSInventors: Gary Gilbert, Jialan Shi, Christian Heegaard, Jan Rasmussen
-
Patent number: 6908899Abstract: A synthetic tetrapeptide having an amino acide sequence, Glycine-Proline-Arginine-Proline (GPRP) has pro-inflammatory effects on human fibroblastic cells, including synovial cells. An amide analog of GPRP is ineffective in inducing, or effective in causing a loss of, pro-inflammatory effects.Type: GrantFiled: August 17, 2001Date of Patent: June 21, 2005Assignee: U.S. Dept. of Veterans AffairsInventor: Theresa H. Smith
-
Publication number: 20050112711Abstract: Elevated levels of GP73 in the sera is diagnostic for hepatocellular carcinoma. An increase in serum GP73 levels over time can also indicate the onset of hepatocellular carcinoma in subjects at risk for the disease.Type: ApplicationFiled: September 3, 2004Publication date: May 26, 2005Applicants: Thomas Jefferson University, Saint Louis University, The USA as represented by the Dept. of Veterans Affairs Office of Research and DevelopmentInventors: Patrick Romano, Timothy Block, Claus Fimmel, Olga Nikolaeva
-
Publication number: 20040185468Abstract: The present invention is directed to methods and compositions related to &agr;7 acetylcholine nicotinic receptor genes, in particular, the human &agr;7 nicotinic acetylcholine receptor gene. The human &agr;7 nicotinic acetylcholine receptor gene is associated with the pathophysiological aspects of the disease schizophrenia. The present invention further provides methods and compositions to screen populations for abnormal &agr;7 alleles, as well as methods and compositions for development of therapeutics.Type: ApplicationFiled: November 26, 2003Publication date: September 23, 2004Applicant: The U. S. A. as represented by the Dept. of Veterans Affairs, Office of General CounselInventors: Sherry Leonard, Robert Freedman
-
Patent number: 6399743Abstract: A cDNA fragment clone of 1583 base pairs with 90-95% sequence homology to the mouse EGFR and a truncated rat EGFR is described. The isolated cDNA is termed ERRP (EFG-Receptor Related Protein). In Northern-blot analysis with poly A+ RNA from different rat tissues, ERRP cDNA hybridized strongly to a mRNA transcript of about 1.8 kb. Maximal expression was noted in the small intestine, followed by colon, liver, gastric mucosa and other tissues. Transfection of ERRP cDNA in HCT-116 cells, a colon cancer cell line, markedly inhibits proliferation in monolayer and in soft agar and attenuates EGF-R tyrosine kinase activity. Transfection of ERRP in HCT-116 also delays tumor growth in SCID mice injected with these cells compared to the vector-transfector control cells. On the other hand, proliferation of the vector-transfected control, but not ERRP transfected HCT cells could be stimulated by TGF-&agr; (10−10M and 10−9M).Type: GrantFiled: May 12, 2000Date of Patent: June 4, 2002Assignee: Dept. of Veterans AffairsInventor: Adhip P. N. Majumdar